Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071263 · ClinicalTrials.gov registry record · Phase 2
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
A Phase 2 study, sponsored by Relypsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT03071263: Completed Phase 2 study, sponsored by Relypsa.
NCT03071263 is a Phase 2 study that has completed, run by Relypsa. The registered enrollment target is 295 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03071263, a Phase 2 study, has completed, sponsored by Relypsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).
Primary Outcome
The proportion of subjects remaining on spironolactone at Week 12 will be compared between treatment groups (spironolactone/patiromer versus spironolactone/placebo). Subjects who discontinued from the study early or discontinued study spironolactone prior to Week 12, for any reason, were considered as not having remained on spironolactone until Week 12.
Interventions
- DRUG Placebo
- DRUG Spironolactone
- DRUG Patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2017-01-23 |
| Est. Completion | 2018-11-27 |
| Phase | Phase 2 |
What the finished NCT03071263 record still lists
NCT03071263 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (122% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03071263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03071263 about?
NCT03071263 is a clinical study titled "Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease". The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure c...
What is the current status of trial NCT03071263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2017-01-23. Estimated completion is 2018-11-27.
What interventions are being tested in trial NCT03071263?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG), Patiromer (DRUG).
Who is sponsoring clinical trial NCT03071263?
This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03071263's enrollment target sits among peer trials
295 189th of 2000 higher than 1,811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI